Lannett Inc. (LCI) Business Metric Overview - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Lannett Inc.

    NYSE: LCI · Real-Time Price · USD
    0.69
    0.03 (4.55%)
    At close: Apr 19, 2023, 9:58 PM

    Lannett Revenue Breakdown

    Period Ending Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Mar 31, 2016 Dec 31, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014 Dec 31, 2013 Sep 30, 2013 Jun 30, 2013 Mar 31, 2013 Dec 31, 2012 Sep 30, 2012
    Analgesic Revenue 2.74M 2.59M 3.42M 3.21M 3.29M 3.92M 5.31M 4.16M 3.84M 3.57M 3.12M 1.87M 2.81M 2.11M 22.78M 25.68M 21.77M 24.06M 18.51M 10.13M 11.31M 11.14M 14.81M 11.97M 12.69M 16.65M 13.08M 9.44M 8.46M 18.33M 18.94M 19.34M 21.33M 16.92M 4.52M 4.52M 6.99M 7.27M 7.1M
    Analgesic Revenue Growth +5.75% -24.30% +6.60% -2.43% -16.00% -26.25% +27.86% +8.34% +7.39% +14.49% +66.49% -33.33% +33.16% -90.73% -11.28% +17.96% -9.50% +29.93% +82.67% -10.36% +1.45% -24.78% +23.72% -5.66% -23.77% +27.29% +38.62% +11.59% -53.87% -3.20% -2.09% -9.32% +26.05% +274.07% +0.11% -35.33% -3.87% +2.38% n/a
    Anti-Psychosis Revenue 2.08M 2.58M 2.62M 2.63M 3.35M 9.75M 14.1M 13.36M 16.57M 16.34M 19.71M 21.25M 21.75M 23.97M 9.42M 6.19M 7.2M 7.65M 8.39M 6.92M 8.82M 7.42M 11.12M 10.55M 10.35M 14.26M 6.08M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Anti-Psychosis Revenue Growth -19.15% -1.72% -0.53% -21.28% -65.69% -30.83% +5.51% -19.36% +1.45% -17.14% -7.23% -2.28% -9.29% +154.37% +52.32% -14.03% -5.95% -8.85% +21.23% -21.47% +18.79% -33.27% +5.39% +1.98% -27.44% +134.72% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Cardiovascular Revenue 13.06M 13.09M 10.88M 12.05M 9.47M 22.34M 22.79M 23.47M 24.51M 24.61M 22.52M 20.1M 18.57M 19.33M 11.73M 10.01M 15.04M 14.12M 16.56M 15.05M 14.55M 15.42M 19.44M 18.98M 18.05M 21.74M 8.62M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Cardiovascular Revenue Growth -0.23% +20.28% -9.73% +27.32% -57.62% -1.95% -2.91% -4.25% -0.43% +9.27% +12.05% +8.27% -3.96% +64.73% +17.24% -33.45% +6.49% -14.73% +10.01% +3.45% -5.60% -20.70% +2.45% +5.12% -16.96% +152.28% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Central Nervous System Revenue 19.31M 21.78M 20.79M 18.02M 15.18M 8.3M 7.84M 7.52M 6.82M 9.5M 3.23M 17.46M 20.75M 18.31M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Central Nervous System Revenue Growth -11.34% +4.75% +15.37% +18.75% +82.92% +5.76% +4.34% +10.22% -28.16% +193.72% -81.48% -15.85% +13.28% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Contract manufacturing revenue Revenue 5.4M 5.32M 3.75M 4.22M 2.62M 14.02M 15.24M 15.05M 16.82M 18.57M 17.1M 21.52M 21.75M 18.08M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Contract manufacturing revenue Revenue Growth +1.43% +41.91% -11.09% +61.09% -81.32% -7.99% +1.28% -10.52% -9.46% +8.63% -20.52% -1.08% +20.31% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Endocrinology Revenue 8.07M 5.83M 7.31M 4.56M 6.79M 6.52M 12.52M 12.18M 10.61M 23.04M 21.93M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Endocrinology Revenue Growth +38.33% -20.25% +60.46% -32.91% +4.17% -47.90% +2.79% +14.75% -53.96% +5.07% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Gastrointestinal Revenue 9.93M 8.72M 7.94M 10.05M 11.71M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Gastrointestinal Revenue Growth +13.95% +9.75% -21.01% -14.13% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Infectious Disease Revenue 2.83M 4.99M 5.07M 3.54M 5.44M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Infectious Disease Revenue Growth -43.36% -1.58% +43.35% -34.98% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Migraine Revenue 2.77M 3.57M 3.32M 3.68M 3.51M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Migraine Revenue Growth -22.55% +7.52% -9.75% +5.02% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Other Revenue 13.34M 10.96M 8.76M 9.13M 13.87M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Other Revenue Growth +21.79% +25.07% -4.01% -34.22% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Respiratory-Allergy-Cough-Cold Revenue 981K 1.47M 1.2M 1.67M 2.31M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Respiratory-Allergy-Cough-Cold Revenue Growth -33.17% +22.13% -28.02% -27.67% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a

    Operating Expense Breakdown

    Period Ending Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
    Selling, General, and Administrative Revenue 20.45M 18.32M 16.7M 25.75M 17.57M 18.79M 18.91M 21.58M 17.64M 13.73M 15.14M 18.59M 22.15M 17.42M 21.31M 22.21M 21.65M 23.2M 20.59M 20.55M 14.11M 28.49M 19.04M 16.52M 17.63M 18.07M 21.26M 21.97M 16.16M 14.67M 15.54M 13.95M 12.2M
    Selling, General, and Administrative Revenue Growth +11.62% +9.70% -35.17% +46.57% -6.49% -0.60% -12.38% +22.34% +28.45% -9.29% -18.58% -16.06% +27.13% -18.24% -4.08% +2.61% -6.67% +12.67% +0.17% +45.64% -50.47% +49.66% +15.25% -6.30% -2.44% -15.01% -3.21% +35.95% +10.17% -5.60% +11.39% +14.29% n/a
    Research and Development Revenue 7.11M 4.93M 7.18M 6.04M 5.81M 4.75M 5.76M 6.02M 5.97M 5.64M 6.54M 6.69M 7.44M 6.91M 8.94M 9.44M 9.84M 9.72M 9.81M 8.34M 2.73M 10.72M 7.41M 11.42M 8.34M 9.94M 12.37M 12.96M 16.5M 9.07M 6.53M 6.98M 9.16M
    Research and Development Revenue Growth +44.18% -31.36% +18.78% +4.08% +22.33% -17.64% -4.20% +0.74% +5.83% -13.69% -2.27% -10.08% +7.75% -22.75% -5.26% -4.09% +1.18% -0.89% +17.70% +205.31% -74.54% +44.72% -35.14% +36.97% -16.09% -19.66% -4.56% -21.42% +81.88% +38.92% -6.53% -23.75% n/a

    Add to Watchlist